Ecological studies of antidepressant treatment and suicidal risks.

Ecological studies of antidepressant treatment and suicidal risks. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Ecological studies of antidepressant treatment and suicidal risks. Abstract Text:

Ross J Baldessarini,Leonardo Tondo,Indiana M Strombom,Svetlana Dominguez,Jan Fawcett,Julio Licinio,Maria A Oquendo,Gary D Tollefson,Robert J Valuck,Mauricio Tohen,Ross J Baldessarini,Leonardo Tondo,Indiana M Strombom,Svetlana Dominguez,Jan Fawcett,Julio Licinio,Maria A Oquendo,Gary D Tollefson,Robert J Valuck,Mauricio Tohen,

Ongoing discussion of potential benefits and risks of antidepressant treatment with respect to suicidal behaviors includes many ecological, or population-based, correlational studies of temporal or regional trends in suicide rates and rates of usage of modern antidepressants including serotonin-reuptake inhibitors (SRIs). Since this body of research has not been compiled and evaluated, we used computerized literature searching to identify 19 relevant published studies. They yielded heterogeneous findings: only 8/19 found significant inverse correlations between rising sales of modern antidepressants in the 1990 s and falling suicide rates not anticipated in the 1980s. Average reductions in suicide rates in the 1990 s (10.7%) and 1980s (10.0%) differed little in 11 studies with data from both eras. Reduction of suicide rates in the 1990 s was unrelated to geographic region, population size, units of analysis, publication year, or growth in antidepressant usage, but was greater with higher initial suicide rates, in men, and in older persons. In the same decade, suicides rates decreased in only half of 79 large countries. Overall, these findings yield limited and inconsistent support for the hypothesis that increased use of modern antidepressants might limit suicide risk, and no evidence that the risk increased. Suicidal risk is determined by complex factors, including access to clinical services, in general, and more comprehensive treatment of depression, in particular. Overall, as with findings from randomized trials and cohort or case-control studies, evidence of specific antisuicidal effects of antidepressant treatment from ecological analyses remains elusive.

Ecological studies of antidepressant treatment and suicidal risks. Publishing Authors By Initials

RJ Baldessarini,L Tondo,IM Strombom,S Dominguez,J Fawcett,J Licinio,MA Oquendo,GD Tollefson,RJ Valuck,M Tohen,RJ Baldessarini,L Tondo,IM Strombom,S Dominguez,J Fawcett,J Licinio,MA Oquendo,GD Tollefson,RJ Valuck,M Tohen,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Ecological studies of antidepressant treatment and suicidal risks. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Harvard review of psychiatry

VOLUME: 15

Page Numbers: 133-45

Journal Abbreviation:

ISSN: 1067-3229

DAY: 9

MONTH: 08

YEAR: 2007

Ecological studies of antidepressant treatment and suicidal risks. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9312789

Ecological studies of antidepressant treatment and suicidal risks. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Ecological studies of antidepressant treatment and suicidal risks. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Ecological studies of antidepressant treatment and suicidal risks.

AFFILIATION: Department of Psychiatry and Neuroscience Program, Harvard Medical School, and International Psychopharmacology Program, McLean Hospital, Belmont, MA 02478, USA. rjb@mclean.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Harv Rev Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Ecological studies of antidepressant treatment and suicidal risks Related Publications

• Clinical trials in bipolar mania: implications in study design and drug development.
• Collaborations between academic psychiatry and the pharmaceutical industry: a perspective from industry.
• Conflicts of interest and the credibility of psychiatric research.
• Ecological studies of antidepressant treatment and suicidal risks.
• Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.
• Olanzapine use in bipolar disorder.
• Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
• Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study.
• Scale matters: the need for a Bipolar Depression Rating Scale (BDRS).
• The empirical redefinition of the psychometric criteria for remission in bipolar disorder.